Autonomix Medical AMIX
Autonomix Medical reports $3.13 million net loss for fiscal Q2 2027
Autonomix Medical (AMIX) filed a 10-Q with the SEC on Nov 10, 2026, 10:34 am ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001437749-26-036033
- Revenue: $0 for the three months ended Sep 30, 2026
- Net loss: $3.13 million for the three months ended Sep 30, 2026
- Cash and equivalents: $7.69 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
Going-concern warning repeated
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the financial statements are issued.”
Also in the prior 10-Q (filed Aug 12, 2026). Prior report Prior on EDGAR
Quoted from the filing.
What changed since last quarter
1 new risk factor
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Operating income and margin | −$3.18M | −$2.77M | −15% |
| Net income | −$3.13M | −$2.73M | −15% |
| Operating cash flow | −$2.61M | −$3.54M | +26% |
| Cash | $7.69M | $3.46M | +122% |
New risk factors (1)
- Feedback received from the FDA through the pre-submission process does not assure acceptance of our proposed regulatory pathway, a determination of substantial equivalence, or authorization to market our products. +11 more paragraphs